別府医療センター 登録レジメン一覧（消化器）
癌腫
膵・胆道癌

レジメンNo

登録日

レジメン名

使用薬剤

SN00102007/2 GEM/4w

GEM1000(d1,8,15)

SN00202007/2 GEM+S-1/3w

GEM1000(d1,8)+S-1(d1-14)

SN00302012/7 GEM+CDDP/3w

GEM1000(d1,8)+CDDP25(d1,8)SN00902021/2 GEM+CDDP+S-1/2w

GEM1000(d1)+CDDP25(d1)+S-1(d1-7)

SN0110-0111

2021/11 mFOLFOX6/2w

L-OHP85(d1)+5FU400/2400(d1)+l-LV200(d1)SN0140-143

2023/1 Durvalumab+GEM+CDDP/3w

Durvalumab1500mg(d1)+GEM1000(d1,8)+CDDP25(d1,8) ※最大8コース、以後Durvalumab単独

膵癌SN00402015/1 GEM+nab-PTX/4w

GEM1000(d1,8,15)+nab-PTX125(d1,8,15)

治癒切除不能膵癌SN00402020/3 mFOLFIRINOX/2w

L-OHP85(d1)+CPT11 150(d1)+l-LV200(d1)+5FU2400)

膵癌

SN0070、0071

2020/7 Onivyde+5-FU+l-LV/2w

Onivyde70(d1)+l-LV(d1)+5-FU2400(d1)SN0130-132

2022/10 GEM+Erlotinib/4w

GEM1000(d1,8,15)+Erlotinib100

SN00502010/10 肝動注lowdose FP

CDDP+5-FU

SN0080-82

2021/1 Atezolizumab+Bev/3w

Atezolizumab1200mg(d1)+Bev15mg/kg(d1)SN0120-121

2022/1 Ramucirumab/2w

Ramucirumab8mg/kg(d1)SN150-153

2023/4 Tremelimumab＋Durvalumab

Tremelimumab300or4mg/kg(d1単回）＋Durvalumab150or20mg/kg(d1)

レジメン登録無し

2016/5 肝動注FP

CDDP20mg/body（ｱｲｴｰｺｰﾙ,d1)+5FU250mg/body(d1-5)

レジメン登録無し

2016/7 肝動注CDDP

CDDP65(アイエーコール,d1）

レジメン登録無し

2016/7 肝動注EPIEPI60(d1)

レジメン登録無し

2016/7 肝動注MIRIPLATINMIRIPLATIN70mg(d1)

レジメン登録無し

2011/2 肝動注ADM+5-FU

ADM+5FU

肝細胞癌

レジメン登録無し
大腸癌

胃癌

Peg-IFN+5-FU肝動注

Peg-IFN+5FU

SG0010,0020

2009/6 mFOLFOX6/2w

L-OHP85(d1)+5FU400/2400(d1)+l-LV200(d1)SG00402009/7 mFOLFOX6+Bevacizumab/2w

L-OHP85(d1)+5FU400/2400(d1)+l-LV200(d1)＋Bev5mg/kg(d1)SG0330,0340

2011/6 mFOLFOX6+Cetuximab/2w

L-OHP85(d1)+5FU400/2400(d1)+l-LV200(d1)＋Cmab400or250(d1,8)SG0350,0360

2011/6 mFOLFOX6+Panitumumab/2w

L-OHP85(d1)+5FU400/2400(d1)+l-LV200(d1)+Pmab6mg/kg(d1)SG00502010/1 XELOX/3w

Capecitabine(d1-14)+L-OHP130(d1)SG00602010/1 XELOX+Bevacizumab/3w

Capecitabine(d1-14)+L-OHP130(d1)+Bev7.5mg/kg(d1)SG00702010/3 SOX+Bevacizumab/3w【臨床試験：SOFT試験】

S-1(d1-14)+L-OHP130(d1)+Bev7.5mg/kg(d1)SG03902011/7 SOX+Cetuximab/3w【臨床試験：KSCC 1002】

Cmab400or250(d1,8,15)+L-OHP130(d1)+S-1(d1-14)

SG0080,0090

2010/4 FOLFIRI/2w

CPT-11 150(d1)+5FU400/2400(d1)+l-LV200(d1)SG01102010/4 FOLFIRI+Bevacizumab/2w

CPT-11 150(d1)+5FU400/2400(d1)+l-LV200(d1)+Bev5mg/kg(d1)SG0310,0320

2011/6 FOLFIRI+Cetuximab/2w

CPT-11 150(d1)+5FU400/2400(d1)+l-LV200(d1)+Cmab400or250(d1,8)SG0370,0380

2011/6 FOLFIRI＋Panitumumab/2w

CPT-11 150(d1)+5FU400/2400(d1)+l-LV200(d1)+Pmab6mg/kg(d1)SG01202010/10 3wIRIS/3w

S-1(d1-14)+CPT-11 150(d1)SG01302009/11 Cetuximab/1w

Cmab400or250(d1)SG01402009/11 Cetuximab＋CPT-11療法/2w

Cmab400or250(d1,8)+CPT-11 150(d1)SG01502009/11 Cetuximab+S-1療法【臨床試験：KSCC0901】

Cmab+S-1

SG01602010/9 Panitumumab/2w

Pmab6mg/kg(d1)SG0491

2014/3 Capecitabine+Bevacizumab/3w

Capecitabine(d1-14)+Bev7.5mg/kg(d1)SG04902017/1 FOLFIRI+Ramucirumab/2w

CPT-11 150(d1)+5FU400/2400(d1)+l-LV200(d1)+Ramucirumab8mg/kg(d1)SG05102017/9 TAS-102+Bev/4w

TAS-102(d1-5,8-12)+Bev(d1,15)

SG05302017/10 UFT/LV+Bev/4w

UFT/LV(d1-21)+Bev(d1,15)

SG05402017/10 S-1+Bev/6w

S-1(d1-28)+Bev(d1,15,29)

SG05202017/10 FOLFIRI+Aflibercept/2w

CPT-11 150(d1)+5FU400/2400(d1)+l-LV200(d1)+Aflibercept4mg/kg(d1)SG01802008/4 S-1+CDDP/5w

S-1(d1-21)+CDDP60(d1)SG05802018/6 IRIS+Bev/3w

S-1(d1-14)+CPT-11 150(d1)+Bev7.5mg/kg

SG06102019/4 XELIRI+Bev/3w

Cape(d1-14)+CPT-11 200(d1)+Bev7.5mg/kg

SG06502019/12 FOLFOXIRI+Bev/2w

L-OHP85(d1)+CPT-11 150(d1)+5FU2400(d1)+l-LV200(d1)＋Bev5mg/kg(d1)SG0680-681

2020/12 Encorafenib/Binimetinib+C-mab/1w

Encorafenib(300mg1日1回)/Binimetinib(45ｍｇ1日2回)+C-mab(400)SG06902020/12 IRIS+Cmab/3w

S-1(d1-14)+CPT-11 150(d1)+Cmab（d1,8,15）

SG07702022/9 Panitumumab+CPT-11/2w

Panitumumab（6mg/kg）+CPT-11(150)SG01802008/4 S-1+CDDP/5w

S-1(d1-21)+CDDP60(d1)SG01902010/4 weekly PTX/4w

PTX80(d1,8,15)

SG04402012/2 XP+HER/3w

Capecitabine(d1-14)+CDDP80(d1)+HER8or6mg(d1)/kg

NG02002013/3 nab-PTX/3w

nab-PTX260(d1)SG04502014/12 S-1+CDDP+HER/3w

S-1(d1-14)+CDDP60(d1)+HER8or6mg/kg(d1)SG04502015/3 G-SOX/3w

S-1(d1-14)+L-OHP100(d1)SG04602015/7 wPTX+Ramucirumab/4w

PTX80(d1,8,15)+Ramucirumab8mg/kg(d1,15)

SG0461

2015/7 Ramucirumab/2w

Ramucirumab8mg/kg(d1)TN0040-3wDOC60/3w

DOC60(d1)SG04802017/1 XELOX+HER/3w

Capecitabine(d1-14)+L-OHP130(d1)+HER8or6mg/kg(d1)SG04702017/1 XELOX/3w

Capecitabine(d1-14)+L-OHP130(d1)SG05002017/9 FOLFOX/2w

L-OHP85(d1)+5FU400/2400(d1)+l-LV200(d1)SG05502017/11 Nivolumab/2w

Nivolumab240mg/body(d1)SG0551

2020/10 【4週毎】Nivolumab/4w

Nivolumab480mg/body(d1)SN0040食道癌--

CDDP+CPT-11/4w

CDDP80(d1)+CPT-11 70(d1,15)

SG05602018/4 nab-PTX+Ramucirumab/4w

nab-PTX100(d1,8,15)+Ramucirumab8mg/kg(d1,15)

SG06602020/2 S-1+DOC/3w

S-1(d1-14)+DOC40(d1)SG07002021/4 Ｔｒａstuzumab Deruxtecan(エンハーツ)/3w

Ｔｒａstuzumab-Deruxtecan6.4mg/kg(d1)SG07102021/12 SOX+Nivolumab/3w

Nivo360(d1)+L-OHP130(d1)+S-1(d1-14)

SG07202021/12 CapeOX+Nivolumab/3w

Nivo360(d1)+L-OHP130(d1)+Cape2000(d1-14)

SG0730,731

2021/12 FOLFOX+Nivolumab/2w

Nivo240(d1)+L-OHP85(d1)+5FU400/2400(d1)+l-LV200(d1)SG0592-593

2022/4 RAM+S-1/6w

Ramucirumab8mg/kg(d1,15,29)+S-1(d1-28)

SG0750-753

2022/7 SOX＋HER/3w

L-OHP130(d1)＋S-1(d1-14)＋HER8or6mg/kg(d1)SG0780-781

2023/1 Pertuzumab+3wHER/3w

Pertuzumab840or420mg/body(d1)+HER8or6mg/kg(d1)SG0790-791

2022/12 CPT-11+Ramucirumab/2w

Ramucirumab8mg/kg(d1)+CPT-11 150(d1)SG0800-801

2022/12 TAS-102+Ramucirumab/4w

Ramucirumab8mg/kg(d1,15)+TAS-102(d1-5,8-12)

SG0211

2010/5 standard FP/4w

CDDP80(d1)+5FU800(d1-5)

SG02202010/9 lowdose FP/1w×4

CDDP6(d1-5)+5FU250(d1-5)

SG02302010/4 3wDOC/3w

DOC70(d1)SG0212

2013

DOC60(d1)+CDDP60(d1)+5FU750(d1-4)

SG0191

2013/1 ｗPTX(100)/8w

PTX100(d1,8,15,22,29,36)

SG0451

2010

CDDP70(d1)+5FU700(d1-4)+Radiation

SG0231

2017/7 DCF(d1,15)/4w

DOC30(d1,15)+CDDP80(d1)+5-FU800(d1-5)

SG05702018/4 5-FU+CDGP/4w

CDGP90(d1)+5FU800(d1-5)

SG06402019/5 FP(NAC)/3w

CDDP80(d1)+5FU800(d1-5)

SG06702020/3 Nivolumab/2w

Nivolumab240mg/body(d1)ｍDCF/3w
FP(+Radiation)/4w

SG0671
軟部腫瘍
膵・消化管神経内分泌腫瘍 SG0590
SG0591
SG0620
SG0630SN0100SN9000-1
MSI-high癌
SG0600SG0601

2020/10 【4週毎】Nivolumab/4w
2013 ADM/3w
2018/10 STZ/6w
2018/10 STZ/1w
2019/5 VP-16+CDDP/3w
2019/5 CPT-11+CDDP/4w
2021/4 STZ+5-FU/6w
2023/6 【適応外】神経内分泌腫瘍mFOLFOX6
2019/1 Pembrolizumab/3w
2020/9 【6週毎】Pembrolizumab/6w

別府医療センター 化学療法委員会

Nivolumab480mg/body(d1)ADM0.4mg/kg(d1,2,3)
STZ500(d1-5)
STZ1000(d1)VP-16 100(d1-3)+CDDP80(d1)CPT-11 60(d1,8,15)+CDDP60(d1)STZ500(d1-5)+5-FU400(d1-5)
L-OHP85(d1)+5FU400/2400(d1)+l-LV200(d1)Pembrolizumab 200mg/body (d1)
Pembrolizumab 400mg/body (d1)

2023年1月

別府医療センター 登録レジメン一覧（乳腺・呼吸器）
癌腫
乳癌

レジメンNo.

登録日

レジメン名

使用薬剤

NG0010-

CMF/4w

CPA(d1-14)+MTX40(d1,8)+5FU600(d1,8)NG0020-EC/3w

EPI90(d1)+CPA600(d1)NG00302010/2 FEC100/3w

EPI100(d1)+CPA500(d1)+5FU500(d1)NG00502008/10 3w HER/3w

HER8or6mg/kg(d1)NG0062-

weekly PTX/1w

PTX80(d1)

NG00742013/3 wPTX+HER/1w

PTX80(d1)+HER4or2mg/kg(d1)NG01502011/7 wPTX+3wHER/3w

PTX80(d1)+HER8or6mg/kg(d1)NG02302011/10 wPTX+2wBEV/4w

PTX90(d1,8,15)+BEV10mg/kg(d1,15)

NG00802008/11 3w DOC/3w

DOC70(d1)NG01602010/4 3wDOC+3wHER/3w

DOC75(d1)+HER8or6mg/kg(d1)NG0100-

VNR/3w

VNR25(d1,8)NG01702011/7 VNR+3wHER/3w

VNR25(1,8)+HER8or6mg/kg(d1)NG01202010/4 TC/3w

DOC75(d1)+CPA600(d1)NG02602012/1 TCH/3w

DOC75(d1)+CBDCA(d1/AUC6)+HER8or6mg/kg(d1)NG01302010/4 GEM/3w

GEM1250(d1,8)NG02202011/8 GEM+3wHER/3w

GEM1250(d1,8)+HER8or6mg/kg(d1)NG01902011/8 Eribulin/3w

Eribulin1.4(d1,8)NG02002011/7 nab-PTX/3w

nab-PTX260(d1)NG02502012/2 nab-PTX+3wHER/3w

nab-PTX260(d1)+HER8or6mg/kg(d1)NG02802013/4 Eribulin+3wHER/3w

Eribulin1.4(d1,8)+HER8or6mg/kg(d1)NG02902013/9 Pertuzumab+HER+DOC/3w

Pertuzumab840or420mg/body(d1)+HER8or6mg/kg(d1)+DOC75(d1)NG03002014/6 T-DM1/3w

T-DM1 3.6mg/kg

NG03102017/9 Pertuzumab+3wHER+wPTX/3w

Pertuzumab840or420mg/body(d1)+HER8or6mg/kg(d1)+PTX80(d1,8,15)

NG03202017/9 Pertuzumab+3wHER+Eribulin/3w

Pertuzumab840or420mg/body(d1)+HER8or6mg/kg(d1)+Eribulin1.4(d1,8)NG03302017/2 AC/3w

DXR60(d1)+CPA600(d1)NG0022

2018/12 dose-dense EC

EPI90(d1)+CPA600(d1)NG0061

2018/12 dose-dense PTX

PTX175(d1)NG3602023/3 【NAC①】Pembrolizumab＋TC

Pembrorizumab200(d1)＋PTX80(d1,8)＋CBDCA1.5(d1,8)NG361

2023/3 【NAC➁】Pembrolizumab＋EC

Pembrorizumab200(d1)＋EPI90(d1)＋CPA600(d1)NG3622023/3 【AC】Pembrolizumab

Pembrorizumab200(d1)NG3502023/3 Pembrolizumab＋PTX

Pembrorizumab200(d1)＋PTX80(d1,8,15,29,36,43,57,64,71)

NG351

2023/3 Pembrolizumab＋GC

Pembrorizumab200(d1)＋GEM1000(d1,8)＋CBDCA2(d1,8)NG352

2023/3 Pembrolizumab＋nabPTX

Pembrorizumab200(d1)＋nabPTX80(d1,8,15,29,36,43,57,64,71)

NG03402020/12 Ｔｒａstuzumab Deruxtecan(エンハーツ)/3w

Ｔｒａstuzumab-Deruxtecan5.4mg/kg(d1)NG0370-0371

2024/2 Pertuzumab+Tmab+DOC(フェスゴ)

Pertuzumab1200or600mg/body(d1)+Tmab600mg/body(d1)+DOC75(d1)NG0372-0373

2024/2 Pertuzumab+Tmab(フェスゴ)

Pertuzumab1200or600mg/body(d1)+Tmab600mg/body(d1)

悪性胸膜中皮腫

KN00102009/4 PEM+CDDP/3w

PEM500(d1)+CDDP75(d1)

非小細胞肺癌

KN00102009/4 PEM+CDDP/3w

PEM500(d1)+CDDP75(d1)KN00202009/6 PEM+CBDCA/3w

PEM500(d1)+CBDCA(d1/AUC5)

KN00302009/9 PEM/3w

PEM500(d1)KN0040

小細胞肺癌

DOC60(d1)

KN00802008/7 GEM+CDDP/3w

GEM1000(d1,8)+CDDP80(d1)KN00902008/8 GEM+CBDCA/3w

GEM1000(d1,8)+CBDCA(d1/AUC5)

KN01102010/7 GEM/3w

GEM1000(d1,8)

KN01202010/7 VNR+CDDP/3w

VNR25(d1,8)+CDDP80(d1)KN01402013/2 PTX+CBDCA/3w

PTX200(d1)+CBDCA(d1/AUC6)

KN01502013/2 PTX+CBDCA+Bev/3w

PTX200(d1)+CBDCA(d1/AUC6)+Bev15mg/kg(d1)KN01602019/9 DOC+CDDP/4w（TRT併用）

DOC40(d1,8)+CDDP40(d1,8)

KG0110-111

2021/6 Ramucirumab+Erlotinib/2w

Ram10mg/kg(d1)/2w+Erlotinib150mg/day

KG01202021/6 Nivolumab+Ipilimumab/6w

Nivolumab360mg/body(d1,22)+Ipilimumab1mg/kg(d1)KG01302021/6 Nivolumab+Ipilimumab+PTX+CBDCA/6w

Nivolumab360mg/body(d1,22)+Ipilimumab1mg/kg(d1)+PTX200(d1,22)+CBDCA(d1,22/AUC=6)

KG01402021/6 Nivolumab+Ipilimumab+PEM+CBDCA/6w

Nivolumab360mg/body(d1,22)+Ipilimumab1mg/kg(d1)+PEM500(d1,22)+CBDCA(d1,22/AUC=5)

KG0160-167

2023/6 Durva+Treme+nab-PTX+CBDCA

Durva1500(d1)+Treme75(d1)+nab-PTX100(d1,8,15)+CBDCA(d1/AUC6)

KG0170-177

2023/6 Durva+Treme+PEM+CBDCA

Durva1500(d1)+Treme75(d1)+PEM(d1)+CBDCA(d1/AUC6)

KG01502023/6 【NAC】Nivo+PTX+CBDCA

Nivo360(d1)+PTX200(d1)+CBDCA(d1/AUC6)

KG01512023/6 【NAC】Nivo+PEM+CBDCA

Nivo360(d1)+PEM500(d1)+CBDCA(d1/AUC6)

KN04002023/11 wCBDCA+PTX(+Radiation)

CBDCA(d1/AUC2)+PTX40(d1)KG01802023/12 Trastuzumab Deruxtecan

Trastuzumab Deruxtecan5.4mg/kg(d1)/3ｗ

KN01802008/7 VP-16+CDDP/3w

VP-16 100(d1-3)+CDDP80(d1)KN01902008/6 VP-16+CBDCA/3w

VP-16 100(d1-3)+CBDCA(d1/AUC5)-

VP-16+CBDCA/3w【透析用】

VP-16 50(d1-3)+CBDCA 300(d1)KN02002008/7 CPT-11+CDDP/4w

CPT-11 60(d1,8,15)+CDDP60(d1)KN02102009/6 CPT-11+CBDCA/4w

CPT-11 60(d1,8,15)+CBDCA(d1/AUC4)

KG00102011/1 S-1+CBDCA/3w

S-1（d1-14)+CBDCA(d1/AUC5)-

CPT-11/4w

CPT-11 60(d1,8,15)

KG00402012/12 PEM+CDDP+Bev/3w

PEM500(d1)+CDDP75(d1)+Bev15mg/kg(d1)KG00602013/3 nab-PTX+CBDCA/3w

nab-PTX100(d1,8,15)+CBDCA(d1/AUC5)

KG00702016/2 Nivolumab/2w

Nivolumab240mg/body(d1)KG0071

2020/10 【4週毎】Nivolumab/4w

Nivolumab480mg/body(d1)KN0240-AMR/3w

AMR40(d1-3)

KG00302018/9 Atezolizumab/3w

Atezolizumab1200mg/body(d1)KG0080-081

2023/11 Durvalumab/4w

Durvalumab1500mg(d1)KG00902019/2 PEM+CDDP+Pembrolizumab/3w

PEM500(d1)+CDDP75(d1)+Pembrolizumab200mg/body(d1)KG0091

2019/2 PEM+CBDCA+Pembrolizumab/3w

PEM500(d1)+CBDCA(d1/AUC5)+Pembrolizumab200mg/body(d1)KG0092

2019/2 PEM+Pembrolizumab/3w

PEM500(d1)+Pembrolizumab200mg/body(d1)KG01002019/7 nab-PTX+CBDCA+Pembrolizumab/3w

nab-PTX100(d1,8,15)+CBDCA(d1/AUC6)+Pembrolizumab200mg/body(d1)KG0101

2019/7 Pembrolizumab/3w

Pembrolizumab200mg/body(d1)KN0250

肺癌（胸水貯留例）

DOC60(d1)+CDDP80(d1)2010/5 DOC/3w

KN0230

悪性胸膜中皮腫

DOC+CDDP/4w

KN0060

KN0191

胸腺腫--

Topotecan/4w

Topotecan1(d1-5)

KN0360-361

2021/6 VP-16+CDDP+Durvalimab/3w

VP-16 100(d1-3)+CDDP80(d1)+Durvalimab1500mg/body(d1)KN0370-371

2021/6 VP-16+CBDCA+Durvalimab/3w

VP-16 80(d1-3)+CBDCA(d1/AUC=5)+Durvalimab1500mg/body(d1)KN0380-381

2021/6 Durvalimab/4w

Durvalimab1500mg/body(d1)KN02702013/4 ADOC/3-4w

CDDP50(d1)+ADM40(d1)+VCR0.6(d3)+CPA700(d4)KN02802011/6 Bevacizumab/3w

Bevacizumab15mg/kg(d1)KN02902011/10 PEM+Bev/3w

PEM500(d1)+Bev15mg/kg(d1)KN02902019/10 Atezolizumab+PTX+CBDCA+Bev/3w

Atezolizumab1200mg/body(d1)+PTX200(d1)+CBDCA(d1/AUC6)+Bev15mg/kg(d1)KN0293

2019/10 Atezolizumab+Bev/3w

Atezolizumab1200mg/body(d1)+Bev15mg/kg(d1)KN03002012/1 PEM+CBDCA+Bev/3w

PEM500(d1)+CBDCA(d1/AUC5)+Bev15mg/kg(d1)KN03102012/12 S-1+CDDP/4w（＋Radiation)

S-1(d1-14)+CDDP60(d1)KN0311

2012/12 S-1+CDDP/5w

S-1(d1-21)+CDDP60(d8)KN03202015/3 nab-PTX/3w

nab-PTX100(d1,8,15)

KN03302017/4 DTX+Ramucirumab/3w

DTX60(d1)+Ramucirumab10mg/kg(d1)KN03002019/10 Atezolizumab+VP-16+CBDCA/3w

Atezolizumab1200mg/body(d1)+VP-16 80(d1-3)+CBDCA(d1/AUC5)

KN0302

2019/10 Atezolizumab/3w

Atezolizumab1200mg/body(d1)KN03402017/4 Pembrolizumab/3w

Pembrolizumab 200mg/body (d1)

KN0341

2020/9 【6週毎】Pembrolizumab/6w

Pembrolizumab400mg/body (d1)

KN03502017/5 Split VP-16+CDDP/3w

VP-16 80(d1-3)+CDDP25(d1-3)

KG00502018/9 Nivolumab/2w

Nivolumab240mg/body(d1)KG0051

2020/10 【4週毎】Nivolumab/4w

Nivolumab480mg/body(d1)

レジメン登録無し

2011/6 hypotonic CDDP(胸腔内投与）CDDP

別府医療センター 化学療法委員会

2023年1月

別府医療センター 登録レジメン一覧（婦・泌尿・耳鼻・リウマチ・皮膚）癌腫
卵巣癌

卵巣癌、子宮体癌
子宮体癌
子宮頚癌

絨毛性疾患

子宮頚部横紋筋肉腫
子宮平滑筋肉腫
子宮癌肉腫
尿路上皮癌

前立腺癌

腎癌

副腎皮質癌
精巣腫瘍
軟部肉腫
頭頚部癌

唾液腺導管癌
関節リウマチ

全身型若年性特発関節炎
顕微鏡的多発血管炎
全身性強皮症
悪性黒色腫

乳房外パジェット病
血管肉腫
悪性神経膠腫悪性軟部肉腫レジメンNo 登録日

レジメン名

使用薬剤

SF00102010/6 TC/3w

PTX175(d1)+CBDCA(d1/AUC5)

SF0020SF0030SF00402010/8 DC/3w
2014/2 DOXIL/4w
2014/2 DOXIL+GEM/3w

DOC70(d1)+CBDCA(d1/AUC5)
DOXIL50(d1)
DOXIL30(d1)+GEM1000(d1,8)SF0050SF0060SF0091

2010/8 CPT-11+VP-16(p.o)/4w
2011/2 TP/4w
2008/8 GEM+DOC/4w

CPT-11 60(d1,15)+VP-16(p.o)［d1-21］
PTX175(d1)+CDDP75(d1)GEM800(d1,8)+DOC70(d8)SF0171
SF01802012/4 3w Topotecan/3w
2013/6 GEM+CBDCA/3w

Topotecan1.5(d1-5)
GEM1000(d1,8)+CBDCA(d1/AUC4)

SF0220SF0191
SF02102011/5 dose-denseTC/3w
2014/6 TC+Bevacizumab/3w
2014/6 Bevacizumab3w

PTX80(d1,8,15)+CBDCA(d1/AUC6)
PTX175(d1)+CBDCA(d1/AUC6)+Bev15mg/kg(d1)Bevacizumab15mg/kg(d1)TN0020
SF0260SF00213wPTX/3w
2017/11 TC+Bevacizumab (CBDCA脱感作療法) /3w
2013/7 DC(CBDCA脱感作療法) /3w

PTX210(d1)PTX175(d1)+CBDCA(d1/AUC6)+Bev15mg/kg(d1)
DOC70(d1)+CBDCA(d1/AUC5)

SF02002017/12 GEM+CBDCA+Bevacizumab / 3w
SF0310-0312 2021/5 Olaparib+Bev/3w

GEM1000(d1,8)+CBDCA(d1/AUC4)+Bev15mg/kg(d1)Olaparib 600mg/day(d1-21)+Bev15mg/kg(d1)SF0360-0361 2023/4 DOXIL+Bev/3w
SF0380-0382 2023/5 Bev+Topotecan/3w
SF03702023/5 GEM/3w
SF0371-373
2023/5 Bev+GEM/3w
SF03902023/6 PLD-C
TN00302013/11 DOC/3w
SF01202011/1 AP/4w
SF03202022/4 Lenvatinib+Pembrolizumab/3w
TN0050wCPT-11/6w
TN00602wCPT-11/2w
SF01002011/1 CDDP+CPT-11/4w
SF0111
2010/8 CDDP(+Radiation)/1w
SF02402016/7 TP+Bev/3w
SF02702018/10 Top・PTX+Bev/3w
SF02802019/6 TC+Bev/3w【Pt製剤不可時】
SF02902019/12 CPT-11+NDP/3w

DOXIL40(d1)+Bev10mg/kg(d,15)
Bev15mg/kg(d1)+Topotecan1.25(d1-5)
GEM1000(d1,8)
Bev15mg/kg(d1)+GEM1000(d1,8)
DOXIL30(d1)+CBDCA(d1/AUC5)
DOC70(d1)
EPI60(d1)+CDDP50(d1)Lenvatinib20(d1-21)+Pembrolizumab200(d1)CPT-11 100(d1,8,15,22)
CPT-11 150(d1)CDDP60(d1)+CPT-11 60(d1,8,15)
CDDP40(d1)PTX175(d1)+CDDP50(d1)+Bev15mg/kg(d1)PTX175(d1)+Top0.75(d1-3)+Bev15mg/kg(d1)PTX175(d1)+CBDCA(d1/AUC6)+Bev15mg/kg(d1)CPT-11 60(d1,8)+NDP80(d1)SF0300SF0340-342
SF03302019/12 NDP(+Radiation)/1w
2022/10 TC+Pembro+Bev/3w
2022/10 TC+Pembro/3w

NDP30(d1)
Pembrolizumab200(d1)+PTX175(d1)+CBDCA(d1/AUC5)+Bev15mg/kg(d1)Pembrolizumab200(d1)+PTX175(d1)+CBDCA(d1/AUC5)

SF0350
SF0410SF01302022/10 Pembro維持療法/3w
2024/1 Cemiplimalb/3w
2010/11 MTX+LF(p.o)/3w

Pembrolizumab200(d1)Cemiplimalb350(d1)MTX1mg/kg(d1,3,5,7)+LF(p.o)［d2,4,6,8］

SF0230SF0231
SF0232

2014/9 MTX/2w
2016/7 ACT-D/2w
2023/0 MTX/1w

MTX20mg/body(d1-5)
ACT-D0.01mg/kg(d1-5)
MTX50mg/㎡(d1)SF0400SF0250SF0150SF0140
HN0010
HN0020
HN0070
HN00802023/8 EMACO/2w
2016/12 VAC/3w
2013/4 GD/3w
2013/4 CDDP+IFM/4w
2010/6 GC/4w
2010/11 3wGC/3w
GEM/4w
2017/6 GC(CBDCA)/3w

VP-16 100(d1-2)+ACT-D0.05mg/body(d1-2)+MTX300(d1)+VCR1(d8)+CPA600(d8)VCR1.5(d1,8,15)+ACT-D0.045mg/kg(d1)+CPA1200(d1)GEM800(d1,8)+DOC70(d1)CDDP50(d1)+IFM1000(d1-5)
GEM1000(d1,8,15)+CDDP70(d2)GEM1000(d1,8)+CDDP70(d2)GEM1000(d1,8,15)
GEM1000(d1,8)+CBDCA(d1/AUC5)

HN0090
HN0100
HN0101
HN0130
HN0150
HN0160
HN0161
HN0030
HN0060
HN0220
HN0050
HN0070
HN0071
HN0110
HN0140
HN170

2017/6 PTX+GEM/4w
2017/1 Pembrolizumab/3w
2020/9 【6週毎】Pembrolizumab/6w
2021/12 Enfortumab Vedotin/4w
2022/7 Avelumab/3w
2022/7 【術後】Nivolumab/2w
2022/7 【術後】Nivolumab/4w
2010/6 3wDOC/3w
2016/6 Cabazitaxel+PSL/3w
2023/12 DOC＋Darolutamide(TRIPLET療法)
2012/2 Temsirolimus/1w
2017/1 Nivolumab/2w
2020/10 【4週毎】Nivolumab/4w
2020/10 Nivolumab+Ipilimumab/3w ★4コース★
2021/12 Nivolumab+Cabozantinib/2w ※Nivo併用は最長2年まで
2022/7 Axitinib＋Pembrolizumab

PTX180(d1)+GEM1000(d1,8,15)
Pembrolizumab200mg(d1)Pembrolizumab400mg(d1)Enfortumab Vedotin1.25mg/kg(d1,8,15)
Avelumab10mg/kg(d1)Nivolumab240(d1)Nivolumab480(d1)DOC70(d1)Cabazitaxel25(d1)+PSL10mg(P.O.)
DOC70(d1)＋Darolutamide1200mg(P.O.)
Temsirolimus 25mg/body(d1)Nivolumab240mg/body(d1)Nivolumab480mg/body(d1)Nivolumab240mg/body(d1)+Ipilimumab 1mg/kg(d1)Nivolumab240mg/body(d1)+Cabozantinib40(d1-14)
Axitinib10mg2×＋Pembrolizumab200(d1)HN0190
HN200
HN201

2023/1 Lenvatinib+Pembrolizumab/3w
2023/3 【術後】Pembrolizumab/3w
2023/3 【術後】【6週毎】Pembrolizumab/6w

Lenvatinib20(d1-21)+Pembrolizumab200(d1)Pembrolizumab200mg(d1)Pembrolizumab400mg(d1)HN0210
HN0211
HN01202023/10 Nivolumab/2w（原発不明）
2023/10 【4週毎】Nivolumab/4w（原発不明）
2021/7 EDP+M/4w

Nivolumab240mg/body(d1)Nivolumab480mg/body(d1)VP-16 100(d2-4)+DXR40(d1)+CDDP40(d3-4)+Mitotane連日

HN0040
HN0080
HN0090
JI0032
JI0033
SG0130
JI0042
JI0050TN0040
JI00602011/3
2015/3
2015/3
2013/42013/42013/42013/4
2010/7
2013/9

CDDP20(d1-5)+VP-16 100(d1-5)+BLM30(d2,9,16)
ADM75(d1)
IFM1500(d1-3)
DOC60(d1)+CDDP70(d1)+5-FU750(d1-5)
DOC50(d1)+CDDP60(d1)+5-FU600(d1-5)
Cet400/200(初回/2回目以降）[d1]
Cet400/200(初回/2回目以降）[d1,8,15]+CDDP100(d1)+5-FU1000(d1-4)
Cet400/200(初回/2回目以降）[d1,8,15]+CBDCA(d1/AUC5)+5-FU1000(d1-4)
DOC60(d1)
CBDCA400(d1)JI0070
JI180
JI0090
JI0100
JI0110
JI0120
JI0130
JI0140
JI0141
JI0150
JI0080
RH0010
RH0020
RH0040
RH0050
RH00702016/4 CDDP+RT/3w
2023/05 wPTX/8w
2019/7 PTX+Cmab/1w
2019/7 Nivolumab/2w
2019/12 PTX+CBDCA+Cmab/3w
2021/5 Pembrolizumab+CBDCA+5-FU/3w
2021/5 Pembrolizumab+FP/3w
2021/5 Pembrolizumab/3w
2021/5 【6週毎】Pembrolizumab/6w
2021/11 weekly CBDCA+RT/1w ★最大7コース★
2018/6 PTX+CBDCA/3w
Infliximab
2010/8 Tocilizumab/4w
2018/2 CPA(500)/4w
2013/5 Abatacept
2018/3 CPA(15)/2w

CDDP100(d1)PTX100(d1,8,15,22,29,36)
PTX80(d1)+Cmab400/250(初回/2回目以降)[d1]Nivolumab240mg/body(d1)PTX100(d1,8)+CBDCA(d1,8/AUC2.5)+Cmab400/200(初回/2回目以降）[d1,8,15]
Pembrolizumab200mg+CBDCA(d1/AUC=5)+5-FU1000(d1-4)
Pembrolizumab200mg+CDDP100(d1)+5-FU1000(d1-4)
Pembrolizumab200mg/body(d1)Pembrolizumab400mg/body(d1)
CBDCA1.5(d1)PTX200(d1)+CBDCA(d1/AUC5)
Infliximab
Tocilizumab
CPA
Abatacept
CPA

RH0030
RH0080
RH0082-083
HF0020
HF0030
HF0040
HF0041
HF00502010/8 Tocilizumab/2w
2015/12 Rituximab/1w
2023/1 Rituximab(先発)/1w
2013/6 DTIC/3w
2014/5 Dac-Tam/4w
2014/9 Nivolumab/3w
2020/10 【4週毎】Nivolumab/4w
2015/10 Ipilimumab/3w

Tocilizumab
Rituximab
Rituximab
DTIC1000(d1)CDDP85(d1)+DTIC160(d2-5)+ACNU60(d2)+Tam(d1-28)
Nivolumab240mg/body(d1)Nivolumab480mg/body(d1)Ipilimumab3mg/kg(d1)

HF0060
HF0061
HF0080
HF0010
HF0050NG0016
HF00702017/4 Pembrolizumab/3w
2020/9 【6週毎】Pembrolizumab/6w
2019/2 Nivolumab+Ipilimumab/3w
2013/6 4wDOC/4w
2014/10 wPTX/4w
2014/7 Bevacizumab+Temozoromide/4w
2017/5 Eribulin/3w

Pembrolizumab200mg(d1)Pembrolizumab400mg/body(d1)Nivolumab80mg/body(d1)+Ipilimumab3mg/kg(d1)
DOC60(d1)
PTX80(d1,8,15)
Bevacizumab10mg/kg(1,15)+Temozoromide(d1-15)
Eribulin(d1,8)

BEP/4w
ADM/3w（単日投与）
IFM/3w
DCF（+Radiation)/4w
DCF/4w
Cet(+Radiation)/1w
Cet+FP/3w
Cet+CBDCA+5-FU/3w
3wDOC/3w
CBDCA/4w

別府医療センター 化学療法委員会

2023年10月

別府医療センター 登録レジメン一覧（血内）
癌腫
ホジキンリンパ腫

非ホジキンリンパ腫

多発性骨髄腫ALアミロイドーシス

急性骨髄性白血病

急性前骨髄性白血病
慢性リンパ性白血病
急性リンパ性白血病

レジメンNo 登録日

レジメン名

使用薬剤

HG00102019/2 Brentuximab Vedotin/3w
Brentuximab Vedotin1.8mg/kg(d1)
HG00702019/3 ABVD/4w
VLB6(d1,15)+DXR25(d1,15)+BLM10(d1,15)+DTIC375(d1,15)
HG0071
2019/3 ABVd/4w
VLB6(d1,15)+DXR25(d1,15)+BLM10(d1,15)+DTIC250(d1,15)
HG0320-321 2020/10 A-AVD/4w
VLB6(d1,15)+DXR25(d1,15)+DTIC375(d1,15)+Brentuximab Vedotin1.2mg/kg(d1,15)
HG00202019/2 Rituximab/1w
Rituximab375(d1)HG00302019/2 Bendamustine/3w
Bendamustine120(d1,2)
HG0031
2019/2 R-Bendamustine/4w (入院用)
Rituximab375(d1)+Bendamustine90(d2,3)
HG0032
2019/2 R-Bendamustine/4w (外来用)
Rituximab375(d1)+Bendamustine90(d1,2)
HG00402019/2 CHOP/3w
VCR1.4(d1)+DXR50(d1)+CPA750(d1)+PSL100mg(d1-5)
HG0041
2019/2 R-CHOP/3w (入院用)
Rituximab375(d2)+VCR1.4(d1)+DXR50(d1)+CPA750(d1)+PSL100mg(d1-5)
HG0042
2019/2 R-CHOP/3w (外来用)
Rituximab375(d1)+VCR1.4(d1)+DXR50(d1)+CPA750(d1)+PSL100mg(d1-5)
HG00502019/2 CVP/3w
VCR1.4(d1)+CPA750(d1)+PSL100mg(d1-5)
HG0051
2019/2 R-CVP/3w
Rituximab375(d2)+VCR1.4(d1)+CPA750(d1)+PSL100mg(d1-5)
HG00602019/2 THP-COP/3w
VCR1.4(d1)+THP50(d1)+CPA750(d1)+PSL100mg(d1-5)
HG0061
2019/2 R-THP-COP/3w (入院用)
Rituximab375(d2)+VCR1.4(d1)+THP50(d1)+CPA750(d1)+PSL100mg(d1-5)
HG0062
2019/2 R-THP-COP/3w (外来用)
Rituximab375(d1)+VCR1.4(d1)+THP50(d1)+CPA750(d1)+PSL100mg(d1-5)
HG01302019/5 MTX大量療法/2w
MTX3500(d1)HG01402019/5 R-GDP/3w
GEM1000(d1,8)+CDDP75(d1)+Rituximab(d8)HG01502019/5 R-ESHAP/3w
Rituximab(d1)+VP-16 40(d1-4)+CDDP25(d1-4)+Ara-C2000(d5)HG02502019/7 mLSG15/4w
VCR(d1)+CPA(d1)+DXR(d1,8)+PSL(d1,8,15-17)MUNC(d8)+VDS(d15)+VP-16(d15-17)+CBDCA(d15)HG02402019/7 Mogamulizumab/1w (他の化学療法と併用字は2W)
Mogamulizumab1mg/kg(d1)HG02602019/7 髄注①/1d
Ara-C40mg/body+MTX15mg/body+PSL10mg/body
HG02302019/7 EPOCH/3w
VP-16 50(d1-4)+VCR0.4(d1-4)+DXR10(d1-4)+CPM750(d5)+PSL60(d1-5)
HG0270-271
2020/5 GB/4w (同日)
Obinutuzumab1000mg/body(d1,8,15)+Bendamustine90(d1,2)
2020/5 GB/4w (Benda先行)
Obinutuzumab1000mg/body(d3,10,17)+Bendamustine90(d1,2)
2020/5 GB/4w (G先行)
Obinutuzumab1000mg/body(d1,8,15)+Bendamustine90(d2,3)
HG02802020/5 Obinutuzumab維持/8w
Obinutuzumab1000mg/body(d1)HG0301-302
2020/6 R-hyper-CVAD/3W
CPA300*2（d2-4）+DXR50（d5）+VCR1.4(d5,12)+RTM375(d1)HG0303-304
2020/6 R-MA/3w
MTX1000(d2)+Ara-C3000*2(d3-4)+RTM375(d1)HG0340-341 2020/10 R-MVP-A【寛解導入】/2w
ＲＴＭ375(d1)+ＭＴＸ3500(d2)+VCR1.4(d2)+PCZ100(d1-7,奇数ｻｲｸﾙ)
HG0342
2020/10 R-MVP-A【地固め】/4w
Ara-C3000(d1,2)
HG0330-332 2020/10 A-CHP/3w
Brentuximab Vedotin1.8mg/kg(d1)+DXR50(d1)+CPA750(d1)+PSL100mg(d1-5)
HG0380-383
2021/7 Pola-BR/3w
Rituximab375(d1)+Pola1.8ｍｇ/kg(d2)+Bendamustine90(d2,3)
HG0390.392
2021/7 <DLBCL>R-Bendamustine/3w (入院用)
Rituximab375(d1)+Bendamustine90(d2,3)
HG0391.393
2021/7 <DLBCL>R-Bendamustine/3w (外来用)
Rituximab375(d1)+Bendamustine90(d1,2)
HG0470-471 2021/12 R-CHOEP/2w,CHOEP/3w
VCR1.4(d1)+DXR50(d1)+VP-16 100(d1-3)+CPA750(d1)+PSL100mg(d1-5)±Rituximab375(d1)HG0460,0462 2021/12 THP-COEP±R/3w
VCR1.4(d1)+THP50(d1)+VP-16 100(d1-3)+CPA750(d1)+PSL100mg(d1-5)±Rituximab375(d1)HG0480-481
2022/1 VR-CAP/3w
Rituximab375(d1)+BOR1.3(d1.4.8..11)+DXR50(d1)+CPA750(d1)+PSL100mg(d1-5)
HG0540-545
2022/9 Pola+R-CHP/3w
Pola1.8(d1)+DXR50(d1)+CPA750(d1)+RTM375(d1)+PSL100(d1-5)
HG06402022/10 CHASE/3w
VP-16 100(d1-3)+CPA1200(d1)+Ara-C2000(d2,3)
HG0641-642 2022/10 CHASER/3w
RTM375(d1)+VP-16 100(d2-4)+CPA1200(d2)+Ara-C2000(d3,4)
HG0630,632
2022/10 R2(1コース目)/4w
RTM375(d1,8,15,22)+LEN20(d1-21)
HG0631,633
2022/10 R2(2-12コース目)/4w
RTM375(d1)+LEN20(d1-21)
HG06502022/12 Romidepsin/4w
Romidepsin14(d1,8,15)
HG0231-0232 2023/8 R-EPOCH/3w
RTM375(d1)+VP-16 50(d1-4)+VCR0.4(d1-4)+DXR10(d1-4)+CPM750(d5)+PSL60(d1-5)
HG06802023/11 SMILE/4w
MTX2000(d1)+IFM1500(d2-4)+VP-16 100(d2-4)+L-ASP6000(d8,10,12,14,16,18,20)+DEX33mg(d2-4)/4w
HG0690-0691 2023/11 R-DeVIC/3w
RTM375(d1)+CBDCA300(d1)+VP-16 100(d1-3)+IFM1500(d1-3)/3w
HG06922023/11 RT-2/3DeVIC/3w
CBDCA200(d1)+VP-16 67(d1-3)+IFM1000(d1-3)+DEX33mg(d1-3)/3w
HG0720-0723 2023/11 Epcolitamab/4w①epcolitamb0.16(d1)+0.8(d8)+48(d15,22)/4w ②-③epcolitamb48(d1,8,15,22) ④-⑨epcolitamb48(d1,15) ⑩-epcolitamb48(d1)HG0080-81
2019/3 BD(寛解導入)/3w
BOR1.3(d1,4,8,11)
HG0082-83
2019/3 BD(維持療法)/5w
BOR1.3(d1,8,15,22)
HG0090-093
2019/3 Azacitidine/4w
Azacitidine75(d1-7)
HG01042022/4 DLd(s.c 1,2クール目)/4w
Dara[s.c]1800mg(d1,8,15,22)
HG01052022/4 DLd(s.c 3-6クール目)/4w
Dara[s.c]1800mg(d1,15)
HG01062022/4 DLd(s.c 7クール目以降)/4w
Dara[s.c]1800mg(d1)HG01102019/3 VRd/3w
BOR1.3(d1,4,8,11)+LEN25mg/kg(d1-14)
HG0120-121
2019/3 CAG/2w
ACR14(d1-4)+Ara-C20(d1-14)
HG06202022/4 DBd(s.c 1-3クール目)/3w
Dara[s.c]1800mg(d1,8,15)＋BOR1.3(d1,4,8,11)
HG06212022/4 DBd(s.c 4-8クール目)/3w
Dara[s.c]1800mg(d1)＋BOR1.3(d1,4,8,11)
HG06222022/4 DBd(s.c 9クール目以降)/3w
Dara[s.c]1800mg(d1)HG03502021/1 DCd(1クール目)/4w
Carfilzomib20(d1,2),56(d8,9,15,16)+Dara8mg/kg(d1,2),16mg/kg(d8,15,22)
HG03512021/1 DCd(2クール目)/4w
Carfilzomib56(d1,2,8,9,15,16)+Dara16mg/kg(d1,8,15,22)
HG03522021/1 DCd(3-6クール目)/4w
Carfilzomib56(d1,2,8,9,15,16)+Dara16mg/kg(d1,15)
HG03532021/1 DCd(7クール目以降)/4w
Carfilzomib56(d1,2,8,9,15,16)+Dara16mg/kg(d1)HG06002021/9 IsaPd（1クール目）/4w
Isa10mg/kg(d1,8,15,22)+Poma4mg(d1-21)
HG06102021/9 IsaPd（2クール目以降）/4w
Isa10mg/kg(d1,15)+Poma4mg(d1-21)
HG05002021/12 PBD(1-8クール目)/3w
Panobinostat20(d1,3,5,8,10,12)＋BOR1.3(d1,4,8,11)+DEX(d1,2,4,5,8,9,11,12)
HG05012021/12 PBD(9-16クール目)/3w
Panobinostat20(d1,3,5,8,10,12)＋BOR1.3(d1,8)+DEX(d1,2,8,9)
HG05102022/2 IsaKd（1クール目）/4w
Isa10mg/kg(d1,8,15,22)+Carfilzomib20(d1,2)+Carfilzomib56(d8,9,15,16)+DEX20mg(d1,2,8,9,15,16,22,23)
HG05112022/2 IsaKd（2クール目以降）/4w
Isa10mg/kg(d1,15)+Carfilzomib56(d1,2,8,9,15,16)+DEX20mg(d1,2,8,9,15,16,22,23)
HG05302022/7 Isa＋d（1クール目）/4w
Isa20mg/kg(d1,8,15,22)＋dex40mg(d1,8,15,22)
HG05312022/7 Isa＋d（2クール目以降）/4w
Isa20mg/kg(d1,15)＋dex40mg(d1,8,15,22)
HG06602023/3 DCEP療法/3w
DEX40(d1-4)＋CPM400(d1-4)＋VP-16 40(d1-4)＋CDDP15(d1-4)/3w
HG06702023/8 KRd(1クール目)/4w
Carfizomib27(d1,2,8,9,15,16)+DEX20(d1,8,15,22)+LEN25mg/kg(d1-21)
HG06712023/8 KRd（2-12クール目）/4w
Carfizomib27(d1,2,8,9,15,16)+DEX20(d1,8,15,22)+LEN25mg/kg(d1-21)
HG07022023/8 KRd（13クール目）/4w
Carfizomib27(d1,2,8,9,15,16)+DEX20(d1,8,15,22)+LEN25mg/kg(d1-21)
HG01112023/9 VRd lite/5w(1-9クール目)
BOR1.3(d1,8,15,22)+LEN(d1-21)+DEX20mg(d1,2,8,9,15,16,22,23)
HG01122023/9 VRd lite/4w(10-15クール目)
BOR1.3(d1,15)+LEN(d1-21)
HG05202022/2 DCyBorD(1-2クール目)/4w
Dara[sc]1800(d1,8,15,22)+CPA300(d1,8,15,22)+BOR1.3(d1,8,15,22)+DEX40mg(d1,8,15,22)
HG05212022/2 DCyBorD(3-6クール目)/4w
Dara[sc]1800(d1,15)+CPA300(d1,8,15,22)+BOR1.3(d1,8,15,22)+DEX40mg(d1,8,15,22)
HG05222022/2 DCyBorD(7クール目以降)/4w ★最大24クールまで★ Dara[sc]1800(d1)HG0160-162
2019/6 DNR+Ara-C寛解導入/4w
DNR50(d1-5)+Ara-C100(d1-7)
HG01802019/6 IDR+Ara-C寛解導入/4w
IDR12(d1-3)+Ara-C100(d1-7)
HG0190-191
2019/6 Ara-C大量療法/4w
Ara-C2000*2(d1-5)
HG0170-172
2019/6 MIT+Ara-C地固め療法/4w
MIT7(d1-3)+Ara-C200(1-5)
HG0200-202
2019/6 DNR+Ara-C地固め療法/4w
DNR50(d1-3)+Ara-C200(d1-5)
HG0210-212
2019/6 ACR+Ara-C地固め療法/4w
ACR20(d1-5)+Ara-C200(d1-5)
HG02202019/6 A-tripleV地固め療法/4w
VP-16 100(d1-5)+Ara-C200(d1-5)+VCR0.8(d8)+VDS2(d10)
HG03702021/4 Venetoclax+Azacitidine/4w
Azacitidine75(d1-7)+Venetoclax po(d1-28)
HG03712021/4 Venetoclax+Ara-C/4w
Ara-C20(d1-10)+Venetoclax po(d1-28)
HG04902022/1 GO/2w ★投与上限2回まで★
GO9(d1)
HG07002023/11 MEC/4w
MIT6(d1-3)+VP-16 80(d1-6)+Ara-C1000(d1-6)/4w
HG07012023/11 miniMEC/4w
MIT8(d1-3)+VP-16 100(d1-5)+Ara-C100(d1-7)/4w
HG03102020/7 ATO寛解導入
ATO 0.15mg/kg/day ※最大60日まで
HG0360-0362 2021/4 Alemtuzumab/1w（投与開始から12wまで）
Alemtuzumab 3→10→30mg/body(d1.3.5)
HG04002021/9 JALSG-ALL202-O Induction 25-59歳/4w
CPA1200（d1）+DNR60(d1-3)+VCR1.3(d1,8,15,22)+L-ASP3000U(d9,11,13,16,18,20)
HG04102021/9 JALSG-ALL202-O C1・C4 25-59歳/3d
Ara-C2000*2（d1-3）+VP-16 100(d1-3)+DEX40(d1-3)+髄注[MTX15mg+DEX4mg](d1)
HG04202021/9 JALSG-ALL202-O C2・C5 25-59歳/3w
MTX3000（d1,15）+VCR1.3(d1,15)+6-MP25(d1-21)+髄注[MTX15mg+DEX4mg](d1,15)
HG04302021/9 JALSG-ALL202-O C3/6w
VCR1.3(d1,8,15)+DXR30(d1,8,15)+CPA1000（d1）+Ara-C75（d29-33,36-40）+髄注[MTX+Ara-C+DEX](d1,29)
HG04402021/9 JALSG-ALL202-O 維持療法/4w
VCR1.3(d1)+MTX.po20(d1,8,15,22)+6-MP60(d1-28)+PSL60(d1-5)
HG0600-0605 2023/8 Blinatumomab/4-8w
Blinatumomab 45kg以上：①9(d1-7)+28(d8-28) ②28(d1-28) 45kg未満：①5(d1-7)+15(d8-28) ②15(d1-28)
HG07102023/12 Inotuzumab ozogamycin1コース目
Inotuzumab ozogamycin0.8(d1)＋0.5(d8,15)/3-4w
HG07112023/12 Inotuzumab ozogamycin2コース目以降(非完解)Inotuzumab ozogamycin0.8(d1)＋0.5(d8,15)/3-4w
HG07122023/12 Inotuzumab ozogamycin2コース目以降(完解)Inotuzumab ozogamycin0.5(d1,8,15)/3-4w

別府医療センター 化学療法委員会

2023年1月